Viewing data from:

BRIELLYN

ANDA

ETHINYL ESTRADIOL; NORETHINDRONE | A090538 | GLENMARK PHARMACEUTICALS LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: TRI-NORINYL 28-DAY(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Briellyn (2023)

Total Spending

$24K

Total Claims

671

Beneficiaries

111

Avg Cost/Unit

$0.89

Spending Trend

$23K(2019)→$25K(2020)→$24K(2021)→$27K(2022)→$24K(2023)

YoY Change:-3.0%

5yr CAGR:+0.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG;0.4MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Mar 22, 2011

No patent or exclusivity listings for this strength.